|
Title
|
|
|
|
The rationale for mTOR inhibition in epithelial ovarian cancer
|
|
|
Author
|
|
|
|
|
|
|
Abstract
|
|
|
|
| The AKT/mTOR signaling pathway is frequently overexpressed in human epithelial ovarian cancer and an attractive target for therapy. In vivo mouse models were confirmative for in vitro findings, where the administration of mTOR inhibitors in ovarian cancer xenografts showed antitumoral as well as antiangiogenic effects. Phase I - II trials are now ongoing with mTOR inhibitors in ovarian cancer patients, some in combination with conventional cytotoxic agents. If further development of mTOR inhibition in ovarian cancer is pursued, studying combinations of mTOR inhibitors with other new targeted therapies would be of interest. mTOR inhibitors in the adjuvant setting could have potential, since, for the moment, there is no standard maintenance therapy in ovarian cancer. A crucial challenge will be to identify strong predictive biomarkers. This review highlights the rationale for the use of mTOR inhibitors in ovarian cancer and summarizes the available preclinical findings. |
|
|
|
Language
|
|
|
|
English
|
|
|
Source (journal)
|
|
|
|
Expert opinion on investigational drugs. - London
|
|
|
Publication
|
|
|
|
London
:
2009
|
|
|
ISSN
|
|
|
|
1354-3784
|
|
|
DOI
|
|
|
|
10.1517/13543780903321508
|
|
|
Volume/pages
|
|
|
|
18
:12
(2009)
, p. 1885-1891
|
|
|
ISI
|
|
|
|
000272750200008
|
|
|
Full text (Publisher's DOI)
|
|
|
|
|
|